Esophagus · 2021 · 19 citations · 16 references
MedicineOncologyPharmacotherapyCancer PharmacologyChemotherapyOncology PharmacotherapyCancer Survival AnalysisEsophageal CancerMetastatic Cancer ManagementMetastatic Disease ManagementMetastatic Esophageal CancerOncologic Outcomes AssessmentPembrolizumab TherapyProgrammed Death-ligand 1 BiomarkerProgrammed Death-ligand 1 InhibitionProgrammed Death-ligand 1 InhibitorsProgrammed Death-ligand 1 SignalingSecond-line Chemotherapy
BACKGROUND: Safe and effective treatments for advanced esophageal cancer are an unmet need in Japan. We report results of a subgroup analysis of Japanese patients enrolled in KEYNOTE-181, a randomized, open-label, phase 3 study of pembrolizumab versus chemotherapy as second-line therapy for patients with advanced or metastatic esophageal cancer whose disease progressed after standard first-line therapy. METHODS: Patients were randomly assigned 1:1 to receive pembrolizumab 200 mg every 3 weeks or investigator's choice of paclitaxel, docetaxel, or irinotecan. Efficacy was evaluated in all Japanese patients and in those with programmed death ligand 1 combined positive score ≥ 10. RESULTS: Of the 152 Japanese patients enrolled (pembrolizumab, n = 77; chemotherapy, n = 75), 150 (98.7%) had squamous cell carcinoma and 79 (52.0%) had combined positive score ≥ 10. At the final analysis, median overall survival was improved among all patients (12.4 vs 8.2 months with pembrolizumab and chemotherapy, respectively; hazard ratio, 0.68; 95% CI 0.48-0.97) and patients with combined positive score ≥ 10 (12.6 vs 8.4 months; hazard ratio, 0.68; 95% CI 0.42-1.10). Fewer patients had any-grade (74.0% vs 95.9%) or grade 3-5 (16.9 vs 50.0%) treatment-related adverse events with pembrolizumab than with chemotherapy. CONCLUSION: Consistent with the global trial results, second-line pembrolizumab therapy showed a survival benefit and a favorable safety profile compared with chemotherapy in Japanese patients with advanced esophageal cancer.
16
Hugo Ford, Andrea Marshall, John Bridgewater et al. · The Lancet Oncology · 2013 · 604 citations · Full text
Public Health, Community Health, Communities Of Practice +14
Esophageal cancer practice guidelines 2017 edited by the Japan Esophageal Society: part 1
Yuko Kitagawa, Takashi Uno, Tsuneo Oyama et al. · Esophagus · 2018 · 543 citations · Full text
Medicine, Oncology, Gastroenterology +14